Joachim Koch

Company: Affimed

Job title: Vice President and Head Discovery Research & Translational Immunology

Seminars:

Case Study: Leveraging the Full Immunity Cycle: ICE® to Engage the Innate & Adaptive Immune System for Effective Anti-Tumoural Responses 9:00 am

Sharing data of the multi-layered immune response of Affimed’s ICE® as mono- and combination therapy Outlining the development of an AB-101 NK cell product combination with AFM13 for CD30+ malignancies, such as HL and CD30-positive PTCL patients Highlighting early data from the combination of AFM24 with the checkpoint inhibitor atezolizumab in the treatment EGFR+ solid…Read more

day: Conference Day Two